EPRX

+ Watchlist + Portfolio

Eupraxia Pharmaceuticals Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.01
52-Week Range: $5.04 – $9.32
Market Cap: $445.53M
P/E (TTM): —
EPS (TTM): -0.99
Dividend Yield: —

Advanced Metrics

Price/Book: 4.35
PEG Ratio: —
Return on Equity: -66.70%
Return on Assets: -43.66%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 16.00
Debt/Equity: 0.01
Total Debt: $1.84M
Free Cash Flow: $-18.93M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $341.63M

EPRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.63M	$20.36M	$16.08M	$21.33M
Selling, General & Admin	$3.99M	$7.48M	$10.92M	$17.10M
Operating Expenses	$17.62M	$27.85M	$27.00M	$38.43M
Operating Income	-$17.62M	-$27.85M	-$27.00M	-$38.43M
EBITDA	-$17.86M	-$27.60M	-$24.97M	-$38.35M
Pretax Income	-$18.99M	-$28.93M	-$25.74M	-$38.59M
Income Tax	$0.00	$36.42K	$1.80K	$19.09K
Net Income	-$18.49M	-$28.22M	-$25.50M	-$38.58M
Diluted EPS	-0.96	-1.17	-0.76	-1.03
Diluted Shares	19.29M	24.15M	33.93M	39.96M

EPRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$18.26M	$19.34M	$33.10M	$80.56M
Receivables	$89.72K	$190.61K	$228.87K	$674.23K
Current Assets	$18.59M	$19.80M	$34.44M	$85.10M
Total Assets	$19.12M	$20.27M	$34.94M	$86.15M
Current Liabilities	$3.06M	$19.37M	$3.10M	$5.63M
Long-Term Debt	$8.80M	—	—	—
Total Debt	$8.99M	$10.45M	$71.86K	$154.36K
Total Liabilities	$11.91M	$19.37M	$3.10M	$5.70M
Retained Earnings	-$77.28M	-$105.50M	-$131.00M	-$169.58M
Shareholders' Equity	$7.79M	$2.22M	$33.40M	$82.04M
Working Capital	$15.53M	$429.18K	$31.33M	$79.47M

EPRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$14.40M	-$20.75M	-$29.99M	-$28.55M
Capital Expenditure	-$235.55K	-$73.38K	-$104.23K	-$588.95K
Free Cash Flow	-$14.63M	-$20.82M	-$30.10M	-$29.14M
Depreciation & Amortisation	$147.89K	$155.53K	$171.72K	$237.72K
Stock-Based Compensation	$1.43M	$1.41M	$3.22M	$9.04M
Investing Cash Flow	$9.83M	-$73.38K	-$75.16K	-$588.95K
Financing Cash Flow	$10.80M	$21.08M	$45.78M	$76.06M
Net Change in Cash	$6.24M	$256.97K	$15.71M	$46.92M

EPRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.85M	$5.20M	$4.42M	$7.87M	$11.17M
Selling, General & Admin	$3.27M	$3.07M	$2.47M	$8.30M	$4.78M
Operating Expenses	$7.12M	$8.26M	$6.88M	$16.16M	$15.96M
Operating Income	-$7.12M	-$8.26M	-$6.88M	-$16.16M	-$15.96M
EBITDA	-$7.08M	-$8.69M	-$6.31M	-$16.64M	-$15.87M
Pretax Income	-$6.76M	-$8.74M	-$6.37M	-$16.71M	-$12.64M
Income Tax	$2.79K	$5.58K	-$623.00	$11.34K	$13.90K
Net Income	-$6.76M	-$8.74M	-$6.36M	-$16.71M	-$12.65M
Diluted EPS	-0.21	-0.26	-0.19	—	-0.23
Diluted Shares	35.69M	35.91M	36.92M	—	56.71M

EPRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$27.45M	$19.77M	$88.96M	$80.56M	$58.50M
Receivables	$238.53K	$134.61K	$139.90K	$674.23K	$663.24K
Current Assets	$28.61M	$22.83M	$91.40M	$85.10M	$142.13M
Total Assets	$29.23M	$23.60M	$92.35M	$86.15M	$145.35M
Current Liabilities	$2.20M	$2.62M	$3.81M	$5.63M	$7.36M
Total Debt	$52.77K	$35.06K	$170.60K	$154.36K	$2.01M
Total Liabilities	$2.20M	$2.62M	$3.91M	$5.70M	$9.17M
Retained Earnings	-$137.77M	-$146.51M	-$152.87M	-$169.58M	-$182.23M
Shareholders' Equity	$28.60M	$22.55M	$90.03M	$82.04M	$137.78M
Working Capital	$26.41M	$20.21M	$87.59M	$79.47M	$134.76M

EPRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$6.00M	-$8.32M	-$4.51M	-$9.73M	-$10.15M
Capital Expenditure	-$169.04K	-$166.22K	-$60.38K	-$193.30K	-$326.95K
Free Cash Flow	-$6.17M	-$8.48M	-$4.57M	-$9.92M	-$10.47M
Depreciation & Amortisation	$46.49K	$55.43K	$62.99K	$72.81K	$90.15K
Stock-Based Compensation	$1.49M	$1.12M	$446.11K	$5.98M	$2.25M
Investing Cash Flow	-$169.04K	-$166.22K	-$60.38K	-$193.30K	-$80.05M
Financing Cash Flow	$429.92K	$239.78K	$73.90M	$1.49M	$68.58M
Net Change in Cash	-$5.74M	-$8.24M	$69.33M	-$8.43M	-$21.62M

Market Snapshot

About

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing locally delivered extended-release products for pain management and inflammatory conditions. The company's proprietary DiffuSphere drug delivery technology platform enables the sustained release of therapeutic agents at the site of disease. Eupraxia's lead product candidates target conditions such as osteoarthritis pain and post-surgical pain. The company focuses on developing non-opioid treatment options that can provide pain relief for weeks or months from a single administration.